What the trial was testing
The PROMISE-MG enrolled 82 patients with myasthenia gravis. The study was sponsored by Duke University and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
More than half of patients felt their quality of life improved with either drug.
The Lancet. Neurology · 2024 · NCT03490539
These findings — that had meaningful quality of life improvements — were published in the The Lancet. Neurology and represent the headline result of the study.
Researchers tracked outcomes across 82 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with myasthenia gravis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Both azathioprine and mycophenolate mofetil are FDA-approved immunosuppressants used for myasthenia gravis. This study found both work similarly well, but they have different side effects. Talk to your neurologist about which might be better for your situation, especially if you're planning pregnancy (mycophenolate can harm a developing baby).
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open myasthenia gravis trials
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.